WOMEN CO-INFECTED WITH HIV AND VHC. PART 2. CLINICAL STATUS AND READINESS TO ANTIVIRAL THERAPY

The materials on psychological and psychosocial status of women with HIV and HCV co-infection [1] with the following assessment of their readiness and ability to undergo treatment of chronic hepatitis C virus and maintenance of treatment compliance to antiretroviral therapy of HIV. The objective of the survey: analysis of the clinical and somatic status of women with HIV and HCV co-infection with the following assessment of their ability to antiviral therapy of CHC and maintenance of treatment compliance to ART taking into account their health status. Materials and methods: the check-up of 100 surveyed women with HIV and HCV co-infection taking into account epidemiologic evidence, laboratory parameters: immunologic (CD4 lymphocyte count), virological (HIV and VHC RNA, VHC genotype) and complete and biochemical blood count was made. Medical prescriptions and response to treatment of CHC were analyzed taking into account the drugs used. Results. Mean age of patients was 36±6 years. Most women had a long-standing co-infection. 1% of women were in the subclinical stage of HIV infection, 64% had stage 4A, 4B — 14% and 4B — 11%. The number of CD4 lymphocytes was 494±29 cells/μl. 78% received ART, and 85% of women showed a high rate of treatment compliance. Among the prevalent HIV-associated diseases were candidiasis (62%), viral (7%) and bacterial diseases (3%); a high percentage (15%) of past tuberculosis of various localization was noted. In 45 cases (53%), HCV RNA was detected in the blood. According to the results of liver elastometry, 74,4% had minimal and moderate fibrosis (METAVIR ≤F2), and a quarter of patients had marked fibrosis (METAVIR F3-F4). Antiviral therapy of chronic hepatitis C was performed in 24% of 100 surveyed women. 62,5% received the combination of pegylated interferon and ribavirin, in 86,6% of cases a sustained virological response was achieved. Treatment with direct antiviral agents was performed in 5 patients, in all cases a sustained virological response was achieved. 85% of patients showed total bilirubin level within the normal range, alanine aminotransferase and aspartate aminotransferase were moderately increased in 41% of women. Most (67,7%) revealed diffuse changes in the structure of the liver, and 36% had pancreatic diffuse changes. Hepatomegaly was found in 24% of cases and splenomegaly was found in 13,3% of women. Comorbid infectious and non-infectious diseases were diagnosed in 59% of women: 32,2% — diseases of the digestive system, 20,3% — diseases of the urogenital system and 18,6% — diseases of the respiratory system. Diseases of the nervous system were diagnosed in 70% of women. Conclusion. The somatic state of women with HIV/HCV co-infection in almost all cases was quite stable, the comorbid pathology was in remission, which gives grounds for expanding indications for prescribing antiviral therapy for CHC. However, many patients are not inclined to undergo treatment with interferon-containing regimens due to the duration of the course and poor tolerance, some of them are focused on treatment with direct-acting antiviral agents and are looking for such a possibility outside the hospital. Therapy with direct-acting antiviral agents with a small number of side effects and high efficacy is a priority for women with HIV/HCV co-infection.

1. Халезова Н.Б., Боева Е.В., Рассохин В.В., Стасишкис Т.А., Ковеленов А.Ю., Студилко Е.В., Беляков Н.А. Женщины с коинфекцией ВИЧ и вирусный гепатит С. Часть 1. Психосоциальная характеристика и готовность к противовирусной терапии // ВИЧ-инфекция и иммуносупрессии. 2018. Т. 10, № 3. С. 30–39. [Khalezova N.B., Boyeva E.V., Rassokhin V.V., Stasishkis Т.А., Kovelenov А.Yu., Studilko E.V., Belyakov N.А. Women co-infected with HIV and VHC. Part 1. Psychosocial characteristic and readiness to antiviral therapy. HIV Infection and Immunosuppressive Disorders, 2018, Vol. 10, No. 3, pp. 30–39 (In Russ.)].

2. Martin J.C., Castilla J., Lopez M., Arranz R., Lahoz G. & Soriano V. Impact of chronic hepatitis C on HIV-1 Disease Progression. HIV Clinical Trials, 2015, рр. 124–131.

3. Hoffman C., Rockstroh J.K. HIV 2014/2015. Hamburg: Medicin focus verlag, 2015, 755 p. URL:http://www.hibook.com.

4. ВИЧ-инфекция в Российской Федерации в 2017 г. / Справка. М: ФНМЦ по профилактике и борьбе со СПИДом ФБУН «Центральный НИИ эпидемиологии» Роспотребнадзора. URL:http://aids-centr.perm.ru/images/4/hiv_in_russia/hiv_in_rf_31.12.2017.pdf. [HIV infection in the Russian Federation in 2017, Reference. Moscow, 2017, FNMC on prevention and fight against AIDS of the Central research Institute of epidemiology of Rospotrebnadzor. URL: http://aids-centr.perm.ru/images/4/hiv_in_russia/hiv_in_rf_31.12.2017.pdf (In Russ.)].

5. Рекомендации по диагностике и лечению взрослых больных гепатитом С. М., 2017. 69 с. [Recommendations for the diagnosis and treatment of adult patients with hepatitis C. Moscow, 2017, 69 p. (in Russ.)].

6. Эсауленко Е.В., Сухорук А.А., Понятишина М.В., Ганченко Г.А. Хронический вирусный гепатит С в Северо-Западном федеральном округе // ВИЧ-инфекция и иммуносупрессии. 2017. Т. 9, № 2. С. 74–81. [Esaulenko E.V., Sukhoruk A.A., Ponyatishina M.V., Ganchenko G.A. Chronic viral hepatitis C in the North-Western Federal district. HIV Infection and Immunosuppressive Disorders, 2017, Vol. 9, No. 2, pp. 74–81 (In Russ.)].

7. Вирус иммунодефицита человека — медицина / Под ред. Н.А.Белякова и А.Г.Рахмановой. СПб.: Балтийский медицинский образовательный центр, 2011. 656 с. [The human immunodeficiency virus — medicine. Eds. N.A.Belyakov and A.G.Rakhmanova. Saint-Petersburg: Baltic medical education center, 2011, 656 p. (In Russ.)].

8. Гепатит С и ВИЧ-инфекция: тактика ведения пациентов с сочетанной инфекцией / Клинический протокол для Европейского региона. ВОЗ, 2006. 53 с. [Hepatitis C and HIV infection: management tactics for co-infected patients. Clinical Protocol for the WHO European region. WHO, 2006, 53 p. (In Russ.)].

9. Плавинский С.Л., Баринова А.М., Ерошина К.М., Кубасова К.А. Заболеваемость ВИЧ-инфекцией, ИППП и гепатитом С среди женщин — потребительниц инъекционных наркотиков, являющихся участницами программ снижения вреда // ВИЧ-инфекция и иммуносупрессии. 2012. Т. 4, № 2. С. 89–94. [Plavinsky S.L., Barinova A.M., Eroshina K.M., Kubasova K.A. Incidence of HIV, STIs and hepatitis C among women consumers of injecting drugs, being participants of harm reduction programmes. HIV Infection and Immunosuppressive Disorders, 2012, Vol. 4, No. 2, pp. 89–94 (In Russ.)].

10. Тимофеева Е.В., Лещенко О.Я. Современные представления о репродуктивном здоровье и потенциале у женщин с ВИЧ-инфекцией и гемоконтактными гепатитами // Бюллетень Восточно-Сибирского научного центра СО РАМН. 2014. № 3 (97). С. 128–133. [Timofeeva E.V., Leshchenko O.Ya. Modern ideas about reproductive health and potential in women with HIV infection and hemocontact hepatitis. Bulletin of the East Siberian Scientific Center of SB RAMS, 2014, Vol. 3 (97), pp. 128–133 (In Russ.)].

11. Ястребова Е.Б., Гутова Л.В. Анализ клинико-анамнестических и иммунологических показателей у женщин репродуктивного возраста с ВИЧ-инфекцией и хроническим вирусным гепатитом С // ВИЧ-инфекция и иммуносупрессии. 2016. Т. 8, № 2. С. 39–46. [Yastrebova E.B., Gutova L.V. Analysis of clinical and immunological indicators in women of reproductive age with HIV infection and chronic viral hepatitis C. HIV Infection and Immunosuppressive Disorders, 2016, Vol. 8, No. 2, pp. 39–46 (In Russ.)].

12. Рахманова А.Г., Яковлев А.А. Хронические вирусные гепатиты С и ВИЧ- инфекция. СПб.: ВВМ, 2011. 164 с. [Rakhmanova A.G., Yakovlev A.A. Chronic viral hepatitis C and HIV infection. Saint-Petersburg: WWM, 2011, 164 p. (In Russ.)].

13. Neukam K., García-Rey S., Cifuentes C., Macías J., Mira J.A., Vázquez M.J. et al. HIV-coinfection leads to a modest increase in plasma HCVRNA load in patients with chronic HCV infection. Antiviral Res., 2012, Vol. 95, No. 3, pp. 212–215.

14. Maier I., Wu G.Y. Hepatitis C and HIV co-infection: A review. World J. Gastroenterol., 2002, Vol. 8, No. 4, рр. 577–579.

15. Lynch S.M., Wu G.Y. Hepatitis C virus: a review of treatment guidelines, cost-effectiveness, and access to therapy. J. Clin. Transl. Hepatol., 2016, Vol. 4, No. 4, pр. 310–319.

16. Жданов К.В., Козлов К.В. Клинические преимущества и экономическая эффективность противовирусной терапии у больных хроническим гепатитом С в условиях бюджетного здравоохранения // ВИЧ-инфекция и иммуносупрессии. 2016. Т. 8, № 2. С. 77–83. [Zhdanov K.V., Kozlov K.V. Clinical advantages and economic efficiency of antiviral therapy in patients with chronic hepatitis C in the conditions of public health. HIV Infection and Immunosuppressive Disorders, 2016, Vol. 8, No. 2, pp. 77–83 (In Russ.)].

17. Новые рекомендации по лечению вирусного гепатита С. Женева, Швейцария: EASL, 2016/EASL, 2017. [New recommendations for the treatment of viral hepatitis C. Geneva, Switzerland: EASL, 2016/EASL, 2017 (In Russ.)].

18. New Recommendations in updated WHO Guidelines for the screening, care and treatment of persons with chronic Hepatitis C Infection. WHO, April 2016, 138 p.

19. 1993. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults: Recommendations and reports. December 18, 1992, 41 (RR-17). URL: https://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm.

20. Радиология и ВИЧ-инфекция / Под ред. Т.Н.Трофимовой, Н.А.Белякова, В.В.Рассохина. СПб.: Балтийский медицинский образовательный центр, 2017. 352 с. [Radiology of HIV infection. Eds. T.N.Trofimova, N.A.Belyakov, V.V. Rassokhin. Saint-Petersburg: Baltic medical education center, 2017, 352 p. (In Russ.)].

21. Combating hepatitis B and C to reach elimination by 2030. WHO, May 2016. URL: http://apps.who.int/iris/bitstream/handle/10665/ 206453/WHO_HIV_2016.04_eng.pdf;jsessionid=049256DBBDF1FBFDDCCC483697128754?sequence=1.

22. Рекомендации по диагностике и лечению взрослых больных гепатитом С. М., 2017. URL: https://arvt.ru/sites/default/files/iia-hcv-2017.pdf. [Recommendations for the diagnosis and treatment of adult patients with hepatitis C. Moscow, 2017. URL: https://arvt.ru/sites/ default/files/iia-hcv-2017.pdf (In Russ.)].

23. Шестакова И.В. Насколько велика опасность использования не зарегистрированных в Российской Федерации лекарственных средств для лечения хронического гепатита С? // Инфекционные болезни: новости, мнения, обучение. 2016. № 2 (15). С. 15–29. [Shestakova I.V. How great is the danger of using medicines not registered in the Russian Federation for the treatment of chronic hepatitis C? Infectious Diseases: News, Opinion, Education, 2016, Vol. 2 (15), pp. 15–29 (In Russ.)].

24. Рудакова А.В., Гусев Д.А., Усков А.Н., Шестакова И.В., Лобзин Ю.В. Эффективность затрат на терапию хронического гепатита С (1 генотип) при фиброзе печени различной степени тяжести // Журнал инфектологии. 2017. Т. 9, № 4. С. 93–101. [Rudakova A.V., Gusev D.A., Uskov A.N., Shestakov I.V., Lobzin Yu.V. Effectiveness in therapy of chronic hepatitis C (genotype 1) when the liver fibrosis of various severity level. Journal of Infectology, 2017, Vol. 9, No. 4, pp. 93–101 (In Russ.)].